A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV Melanoma in the Adjuvant Setting

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502620-49-00

Acronym

20220083

Enrollment

156

Registered

2023-06-21

Start date

2023-08-01

Completion date

2025-10-29

Last updated

2025-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resected Melanoma Stage III or Stage IV

None listed

Sex/Gender

All

Age

18 Years to No maximum

Croatia, France, Germany, Italy, Lithuania, Netherlands, Romania, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026